S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
NASDAQ:GPCR

Structure Therapeutics (GPCR) Stock Forecast, Price & News

$50.42
+12.95 (+34.56%)
(As of 09/29/2023 ET)
Compare
Today's Range
$48.55
$65.51
50-Day Range
$26.49
$50.42
52-Week Range
$20.80
$65.51
Volume
9.97 million shs
Average Volume
545,955 shs
Market Capitalization
$1.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.50

Structure Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
18.0% Upside
$59.50 Price Target
Short Interest
Bearish
6.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Structure Therapeutics in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.88) to ($0.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.37 out of 5 stars

Medical Sector

930th out of 971 stocks

Pharmaceutical Preparations Industry

427th out of 445 stocks


GPCR stock logo

About Structure Therapeutics (NASDAQ:GPCR) Stock

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.

GPCR Price History

GPCR Stock News Headlines

Structure Therapeutics (NASDAQ:GPCR) PT Raised to $97.00
U.S. Loses to China in Shocking WAR GAMES
=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
U.S. Loses to China in Shocking WAR GAMES
=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
Why Shares of Structure Therapeutics Are Soaring on Friday
Structure Therapeutics Sets $300 Mln Private Placement Equity Financing
Qualcomm Unveils New Corporate Structure
See More Headlines
Receive GPCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GPCR Company Calendar

Last Earnings
8/10/2023
Today
10/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GPCR
Fax
N/A
Employees
77
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$59.50
High Stock Price Forecast
$97.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+18.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.93 billion
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Raymond C. Stevens Ph.D. (Age 59)
    CEO & Director
    Comp: $747.33k
  • Dr. Yingli Ma Ph.D. (Age 49)
    Chief Technology Officer
    Comp: $497.58k
  • Dr. Mark A. Bach M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $628.37k
  • Mr. Jun S. Yoon (Age 45)
    Co- Founder, CFO & Sec.
  • Dr. Xichen Lin Ph.D. (Age 49)
    Chief Scientific Officer
  • Mr. Tony Peng
    Sr. VP of Legal
  • Dr. Hui Lei Ph.D.
    Sr. VP of Chemistry
  • Ms. Melita Sun Jung (Age 46)
    Chief Bus. Officer
  • Dr. Fang Zhang Ph.D.
    Exec. VP & Head of Biology
  • Ms. Lani Ibarra
    Sr. VP of Clinical Devel. Operations













GPCR Stock - Frequently Asked Questions

Should I buy or sell Structure Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GPCR shares.
View GPCR analyst ratings
or view top-rated stocks.

What is Structure Therapeutics' stock price forecast for 2023?

6 brokers have issued 1 year target prices for Structure Therapeutics' shares. Their GPCR share price forecasts range from $33.00 to $97.00. On average, they anticipate the company's stock price to reach $59.50 in the next twelve months. This suggests a possible upside of 18.0% from the stock's current price.
View analysts price targets for GPCR
or view top-rated stocks among Wall Street analysts.

How have GPCR shares performed in 2023?

Structure Therapeutics' stock was trading at $26.00 on January 1st, 2023. Since then, GPCR shares have increased by 93.9% and is now trading at $50.42.
View the best growth stocks for 2023 here
.

How were Structure Therapeutics' earnings last quarter?

Structure Therapeutics Inc. (NASDAQ:GPCR) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01.

What ETF holds Structure Therapeutics' stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 3,513 shares of GPCR stock, representing 0.96% of its portfolio.

When did Structure Therapeutics IPO?

(GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share.

What is Structure Therapeutics' stock symbol?

Structure Therapeutics trades on the NASDAQ under the ticker symbol "GPCR."

When did the company's lock-up period expire?

Structure Therapeutics' lock-up period expired on Wednesday, August 2nd. Structure Therapeutics had issued 10,740,000 shares in its initial public offering on February 3rd. The total size of the offering was $161,100,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

How do I buy shares of Structure Therapeutics?

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Structure Therapeutics' stock price today?

One share of GPCR stock can currently be purchased for approximately $50.42.

How much money does Structure Therapeutics make?

Structure Therapeutics (NASDAQ:GPCR) has a market capitalization of $1.93 billion.

How can I contact Structure Therapeutics?

The official website for the company is www.structuretx.com. The company can be reached via phone at 628-229-9277 or via email at ir@structuretx.com.

This page (NASDAQ:GPCR) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -